Clinical Trials Logo

Giant Lymph Node Hyperplasia clinical trials

View clinical trials related to Giant Lymph Node Hyperplasia.

Filter by:

NCT ID: NCT00891280 Recruiting - Breast Cancer Clinical Trials

Dose-escalation Study of Oral CX-4945

Start date: February 2009
Phase: Phase 1
Study type: Interventional

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.

NCT ID: NCT00412321 Completed - Multiple Myeloma Clinical Trials

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Start date: May 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.

NCT ID: NCT00361933 Withdrawn - Clinical trials for Giant Lymph Node Hyperplasia

Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

Start date: December 2008
Phase: Phase 4
Study type: Interventional

The purpose of the study is to learn whether people who are experiencing an MCD (multicentric Castleman's Disease) flare will improve after taking valganciclovir. MCD is a type of inflammatory disease associated with Human Herpesvirus 8 (HHV-8). Valganciclovir is FDA approved for treating a different type of Human Herpesvirus, but not approved for the treatment of HHV-8. It is therefore considered experimental in this study.

NCT ID: NCT00127569 Terminated - HIV Infections Clinical Trials

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy. Efficacy is assessed by the complete response rate at day 60. The patients are followed until day 365.

NCT ID: NCT00002652 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Start date: May 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.